Reduction of CA125 Levels During Neoadjuvant Chemotherapy Can Predict Cytoreduction to No Visible Residual Disease in Patients with Advanced Epithelial Ovarian Cancer, Primary Carcinoma of Fallopian tube and Peritoneal Carcinoma

Background and aims. To determine whether reduction of CA125 levels is a predictive factor for cytoreduction to no visible residual disease (NVRD) and chemotherapeutic sensitivity in advanced epithelial ovarian carcinoma (EOC), primary carcinoma of fallopian tube and peritoneal carcinoma patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Jing, Yin, Jie, Song, Xiao, Jin, Ying, Li, Yan, Pan, Lingya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5166544/
https://www.ncbi.nlm.nih.gov/pubmed/27994671
http://dx.doi.org/10.7150/jca.16761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5166544/
https://www.ncbi.nlm.nih.gov/pubmed/27994671
http://dx.doi.org/10.7150/jca.16761

Ejemplares similares